Make sure you have a pot of coffee ready. Martin Shkreli will join PreMarket Prep for an exclusive interview on Monday at 8:15 a.m. ET.
Last week, Retrophin Inc announced positive results from sparsentan, a mid-stage clinical trial in patients suffering from a rare kidney disease.
Shkreli is the co-founder and ex-CEO of Retrophin, but is faced charges of withholding information from investors. The Street’s Adam Feuerstein credited Shkreli with designing the now-successful clinical trial. Feuerstein suggested that if the company’s drug is approved, patients suffering from rare liver diseases “will have him to thank.”
